A Phase 1-2 Study of TNG462 Plus Other Medications in People With Pancreatic or Non-Small Cell Lung Cancer

Full Title

A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG462 in Combination with Other Agents in Patients with Pancreatic or Non-Small Cell Lung Cancer with MTAP Loss and RAS Mutation

Purpose

Researchers are assessing different doses of TNG462 to give with daraxonrasib or zoldonrasib in people with advanced cancer. The people in this study have pancreatic cancer or non-small cell lung cancer (NSCLC) that spread beyond its original location. In addition, their cancers have a mutation (change) in the RAS gene and are missing a protein called MTAP.

TNG462 is designed to target and kill cancer cells that do not make the MTAP protein. Daraxonrasib and zoldonrasib target the proteins made by a mutated RAS gene. They may slow or stop cancer growth by preventing the RAS protein from sending growth signals.

If you take part in this study, you will take TNG462 with either daraxonrasib or zoldonrasib (but not both). All three drugs are taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have pancreatic cancer or NSCLC that has spread beyond its original location.
• Have a tumor that is missing MTAP and has a KRAS, NRAS, or HRAS mutation.
• Have recovered from the serious side effects of prior therapies before taking the study treatment.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Eileen O’Reilly’s office at 646-888-4182.